Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Journal of Medicinal Chemistry
|
November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma
James S Scott, Sébastien L Degorce, Rana Anjum, et al.
Journal of Medicinal Chemistry
|
October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement
Bernard Barlaam, Chris De Savi, Allan Dishington, et al.
Nature
|
September 16, 2021
Rational design of a new antibiotic class for drug-resistant infections
Thomas F Durand-Reville, Alita A Miller, John P O'Donnell, et al.
Journal of Medicinal Chemistry
|
May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
William McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry
|
July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
William McCoull, Roman D Abrams, Erica Anderson, et al.
ACS Chemical Biology
|
October 19, 2018
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
William McCoull, Tony Cheung, Erica Anderson, et al.
Journal of Medicinal Chemistry
|
December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam, Robert Casella, Justin Cidado, et al.
ACS Medicinal Chemistry Letters
|
November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Journal of Medicinal Chemistry
|
November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma
James S Scott, Sébastien L Degorce, Rana Anjum, et al.
Journal of Medicinal Chemistry
|
October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement
Bernard Barlaam, Chris De Savi, Allan Dishington, et al.
Nature
|
September 16, 2021
Rational design of a new antibiotic class for drug-resistant infections
Thomas F Durand-Reville, Alita A Miller, John P O'Donnell, et al.
Journal of Medicinal Chemistry
|
May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
William McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry
|
July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors
William McCoull, Roman D Abrams, Erica Anderson, et al.
ACS Chemical Biology
|
October 19, 2018
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
William McCoull, Tony Cheung, Erica Anderson, et al.
Journal of Medicinal Chemistry
|
December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam, Robert Casella, Justin Cidado, et al.
ACS Medicinal Chemistry Letters
|
November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Page
of 5